EPRX vs ERNA

Eupraxia Pharmaceuticals Inc. vs Ernexa Therapeutics Inc. — Valuation Comparison 2026

EPRX

Biotechnology
Eupraxia Pharmaceuticals Inc.
Quality
1.9
out of 10
Value Trap
6
SAFE
Price
$7.38
Last close
Models
7/13
Active
VS

ERNA

Biotechnology
Ernexa Therapeutics Inc.
Quality
4.9
out of 10
Value Trap
34
LOW
Price
$11.66
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType EPRX Fair ValueEPRX Upside ERNA Fair ValueERNA Upside
Bayesian DCF Intrinsic $1.95 -73.5% $3.80 -67.4%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.52 -78.8% $0.01 -92.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $4.13 -42.5% $13.57 +16.4%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for EPRX vs ERNA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EPRX vs ERNA — Which Stock Is More Undervalued?

ERNA scores higher with a 4.9/10 quality rating vs EPRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Eupraxia Pharmaceuticals Inc. (EPRX) and Ernexa Therapeutics Inc. (ERNA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EPRX currently trades at $7.38 with a QOC of 1.9/10, while ERNA trades at $11.66 with a QOC of 4.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).